Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 18/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 15/20 | 0.45 |
| ▸ | ITGAV | P06756 | 11/20 | 0.45 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.45 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6504293 | 0.88 | ITGB3 (0.57) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL6494179 | 0.86 | ITGB3 (0.42) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL6494126 | 0.80 | ITGB3 (0.51) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL7449118 | 0.78 | ITGB3 (0.60) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL7451411 | 0.75 | ITGB3 (0.60) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL7447985 | 0.75 | ITGB3 (0.58) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL7452831 | 0.75 | ITGB3 (0.47) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL7444692 | 0.74 | ITGB3 (0.62) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL7451673 | 0.74 | ITGB3 (0.62) | ITGB3ITGA2BITGAVITGB5ITGB1 | |
| SCHEMBL7222365 | 0.74 | ITGB3 (0.38) | ITGB3ITGA2BITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960594-B2 | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer | SHIRE BIOCHEM INC. (CA) | 2005-11-01 | — | — | US | disclosed |
| US-20020137947-A1 | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer | BIOCHEM PHARMA INC. | 2002-09-26 | — | — | US | disclosed |
| EP-1091952-A1 | THIOPHENE AND FURAN 2,5-DICARBOXAMIDES USEFUL IN THE TREATMENT OF CANCER | BIOCHEM PHARMA INC (CA) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000000486-A1 | THIOPHENE AND FURAN 2,5-DICARBOXAMIDES USEFUL IN THE TREATMENT OF CANCER | BIOCHEM PHARMA INC. (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137947-A1 | Thiophene and furan 2,5-dicarboxamides useful in the treatment of cancer | ITGB5, ITGB2, ITGA2 | ITGB3 12/4885ITGA2B 10/4885ITGAV 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.